Medical composition for treating oral mucosa diseases and preparation method and purpose of medical composition

Abstract

The invention provides a medical composition for treating oral mucosa diseases. The medical composition is prepared from the following raw material medicines in parts by weight of 5-50 parts of radixbupleuri, 3-30 parts of rhizoma cimicifugae, 8-80 parts of radix astragali, 3-30 parts of poria cocos, 3-30 parts of ginseng, 3-30 parts of radix glycyrrhizae preparata, 3-30 parts of swordlike atractylodes rhizomes, 3-30 parts of bighead atractylodes rhizomes, 3-30 parts of fructus aurantii, 3-30 parts of rhizoma coptidis, 3-30 parts of radix scutellariae, 3-30 parts of cinnamon and 5-50 parts ofherba cistanches. The invention also further discloses a preparation method and purpose of the medical composition. The traditional Chinese medicine composition provided by the invention is novel informula and simple in composition, has the advantages of being low in cost, notable in treatment effects, free from toxic and side effects and the like, tolerance is not easy to produce, and a new medication selection is provided for clinical treatment of the oral mucosa diseases of oral lichen planus, dental ulcer or chronic periodontitis and the like.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for treating oral mucosal diseases, a preparation method and application thereof. Background technique [0002] Oral mucosal disease refers to the damage of the mucous membrane in the oral cavity. Specific symptoms include ulceration of the mouth and tongue, dry and cracked tongue, etc., which often lead to oral diseases such as oral lichen planus, oral ulcers, stomatitis, and cheilitis. It belongs to the category of common and frequently-occurring diseases in clinical practice. . [0003] Oral lichen planus mainly occurs in adults over the age of 40, and its prevalence is about 0.51%. According to epidemiological surveys, the malignant transformation rate of this disease is about 0.2% to 1.5%, and WHO has defined it as a precancerous state disease. At present, Western medicine mostly uses glucocorticoids, immune enhancers, vitamins, etc. for the treatment ...

AI Technical Summary

Problems solved by technology

[0006] Theoretically speaking, the above-mentioned disclosed patent formula has good clinical efficacy in the treatment of oral lichen planus, periodontitis, etc., but the above-mentioned formula has a large number of medicinal flavors, a single direction of action, and relatively high production costs. It is difficult to control its impurity content in large-scale production, so there is an urgent need for a pharmaceutical composition with less medicinal taste, good balance, and significant clinical efficacy

At present, there is no relevant report on the treatment of oral mucosal diseases with Bupleurum, Cimicifuga, Radix Astragali, Poria, Ginseng, Radix Glycyrrhizae, Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizome, Atractylodes Atractylodes Rhizome, Fructus Aurantii, Coptidis Rhizome, Scutellaria Baicalensis, Cinnamon, and Cistanche.

Images